

ADDENDUM: Apple Health Preferred Drug List (AHPDL) Class Names

The drug classes listed in the agenda have been shortened to allow for easier organization of the topics. The classes listed below reflect the exact naming used by the Washington State Health Care Authority for the AHPDL.

ONCOLOGY AGENTS : ANDROGEN BIOSYNTHESIS INHIBITORS - ORAL
ONCOLOGY AGENTS : ANTIANDROGENS - ORAL
ONCOLOGY AGENTS : ANTINEOPLASTICS - MISC COMBINATIONS - ORAL
ONCOLOGY AGENTS : BRAF KINASE INHIBITORS - ORAL
ONCOLOGY AGENTS : CYCLIN DEPENDENT KINASES (CDK) INHIBITORS - ORAL
ONCOLOGY AGENTS : FGFR KINASE INHIBITORS - ORAL
ONCOLOGY AGENTS : HEDGEHOG PATHWAY INHIBITORS - ORAL
ONCOLOGY AGENTS : MEK INHIBITORS - ORAL
ONCOLOGY AGENTS : MTOR KINASE INHIBITORS - ORAL
ONCOLOGY AGENTS : MULTIKINASE INHIBITORS - ORAL
ONCOLOGY AGENTS : POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS - ORAL
ONCOLOGY AGENTS : RETINOIDS - ORAL
ONCOLOGY AGENTS : TOPOISOMERASE INHIBITORS - ORAL
ONCOLOGY AGENTS : TROPOMYOSIN RECEPTOR KINASE INHIBITORS - ORAL
ONCOLOGY AGENTS : TYROSINE KINASE INHIBITORS - ORAL
OPHTHALMIC AGENTS : GLAUCOMA AGENTS
OPHTHALMIC AGENTS : IMMUNOMODULATORS
RESPIRATORY AGENTS : PULMONARY FIBROSING AGENTS
SMOKING DETERRENTS : MISC - OTHER